Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Gain on sale of PREBOOST® business

Impairment of intangible assets

Provision for (recovery of) credit losses

Gain on sale of ENTADFI® assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Veru

Veru, Inc. is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer, VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer, and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT. The firm’s breast cancer drug candidates include: Enobosarm, an oral, new chemical entity, selective androgen receptor agonist that targets the androgen receptor in AR+/ER+/HER2-hormone sensitive metastatic breast cancer without unwanted virilizing side effects, and VERU 111 for triple negative metastatic breast cancer that has become resistant to taxane IV chemotherapy. It is also advancing the new drug formulation TADFYN, tadalafil and finasteride combination capsules for the treatment of men with lower urinary tract symptoms. The company’s sexual health business’ commercial product is the FC2 Female Condom/FC2 Internal Condom, an FDA-approved product for dual protection against unintended pregnancy and the transmission of sexually transmitted infections which is sold commercially and in the public health sector both in the U.S. and globally. Veru was founded by William R. Gargiulo, Jr. and O. B. Parrish in 1996 and is headquartered in Miami, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Veru reports positive Phase III results for sabizabulin in COVID-19

Veru's positive Phase III trial results for sabizabulin in COVID-19 highlight its potential in reducing mortality.
Financially, challenges persist with decreased revenues and increased expenses, but the company is focused on growth strategies.
The company's strengths lie in sabizabulin's unique mechanism, clinical trial prioritization, and revenue generation plans.
Opportunities for Veru include commercializing sabizabulin, driving revenue growth, and advancing oncology trials.

Veru reports Q2 financial challenges but shows promise in clinical developments

Veru Inc. faced financial challenges in Q2 2023 with decreased net revenues and significant operating losses, prompting efforts to manage costs and explore strategic options.
Despite the financial hurdles, the company demonstrated strengths in clinical developments, securing additional funding, and pursuing growth opportunities in breast cancer and viral ARDS treatments.
Veru's focus on increasing revenues through marketing efforts, expanding distribution channels, and seeking strategic partnerships positions the company for future growth and success in the pharmaceutical industry.

Veru reports mixed Q3 results, eyes partnerships and market expansion

Veru Inc. faced challenges with a decrease in net revenues but achieved a net income for Q3 2023.
Strengths lie in promising results of enobosarm and sabizabulin studies, FDA clarity, and improved cash position.
Opportunities include expanding evaluation of sabizabulin, seeking partnerships, and market expansion through tenders.
The company needs to address challenges of net losses, high operating expenses, and maintaining adequate cash reserves.

Veru Inc. reports Q4 earnings, pursues partnerships for drug development

Veru Inc. reported a decrease in net revenues but secured significant funding through a successful public offering. Their drug development program, particularly enobosarm and sabizabulin, holds promise for multiple medical applications. The pursuit of partnerships and the potential for combination treatments present opportunities for future growth.

Veru Inc. reports Q1 growth, seeks partners for enobosarm study

Veru Inc. demonstrates financial progress and strategic initiatives in drug development, positioning itself for future growth and innovation.
The company's focus on enobosarm's potential in weight loss and oncology, along with seeking partnerships, reflects a proactive approach to advancing its pipeline.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed for two indications: (i) Phase 2b clinical study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness and (ii) subject to the availability of sufficient funding, Phase 3 clinical trial of enobosarm for the treatment of androgen receptor positive (AR+), estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed as a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS. The company was founded by William R. Gargiulo, Jr., O. B. Parrish, and Harry Fisch in 1971 and is headquartered in Miami, FL.

Dr. Mitchell Steiner, chief executive of drugmaker Veru, said a Phase 2 trial of VERU-111 showed an 82% relative reduction in Covid-19 patient mortality versus placebo.

Veru reports cancer drug has high potential to reduce Covid-19 deaths

The stock price of Veru Inc (NASDAQ: VERU) is trading at over 20% pre-market. This is why it happened.

VERU Stock Price Increases Over 20% Pre-Market: Why It Happened

Veru Inc (NASDAQ: VERU) rises sharply after announcing positive efficacy and safety results from a Phase 2 trial evaluating VERU-111 versus placebo in approximately 40 hospitalized patients at high risk for Acute Respiratory Distress Syndrome from SARS-CoV-2. Data showed that VERU-111 treatment compared to placebo had a statistically significant and clinically meaningful reduction in the proportion of treatment failures with a 30% treatment failure rate in the placebo group compared to a 5.6% in the VERU-111 treated group at Day 29.

Veru's COVID-19 Drug Candidate Shows High Relative Reduction In Treatment Failures, Mortality In Mid-Stage Study

– Potential for two-pronged action against COVID-19 as an antiviral and  anti-inflammatory agent supported by Phase 2 clinical study results –

Veru Reports Positive Phase 2 Clinical Results of VERU-111 in Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

Female Health Company The (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Female Health Company The (VERU) Report Negative Earnings Next Week? What You Should Know

MIAMI, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that it will report financial results for its fiscal 2021 first quarter ended December 31, 2020, on Wednesday, February 10, 2021 before the market opens.  Veru's management will host a conference call that same day at 8 a.m. ET to review the Company's performance and to answer questions. The call will also be accessible via webcast.

Veru to Report Fiscal 2021 First-Quarter Financial Results, Host Conference Call on February 10th

After a stellar 3x rise since the March 23 levels of last year, at the current price of around $10 per share we believe Veru Inc. stock, a biopharmaceuticals company focused on oncology medicines, has reached its near-term potential. Veru stock has rallied from $3 to $10, significantly.

Is The Rally In Veru Overdone?

MIAMI, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the Company will present at the H.C. Wainwright Bioconnect 2021 Conference. The presentation will be available on-demand through the Conference from January 11-14, 2021 starting at 6:00 a.m. ET.

Veru to Present at the H.C. Wainwright Bioconnect 2021 Conference on January 11th, 2021

Investors need to pay close attention to Veru (VERU) stock based on the movements in the options market lately.

Implied Volatility Surging for Veru (VERU) Stock Options

Shares of Veru Inc. soared 51.4% toward a seven-year high on massive volume, after the biopharmaceutical company announced positive results from a Phase 2 study of its treatment of breast cancer. Trading volume was 105 million shares, enough to make the stock the most actively traded on the Nasdaq exchange.

Veru's stock soars again on heavy volume after positive results of breast cancer treatment

AnPac Bio-Medical Science Co

Aerpio Pharmaceuticals Inc

Arvinas Inc

Synlogic

Even as the broader market trades higher in reaction to the availability of the first coronavirus vaccine under emergency use authorization, a slew of biopharma stocks are moving on company-specific updates. Arvinas Inc (NASDAQ: ARVN): The smid-cap biopharma announced clinical program updates for its protein degraders ARV-471 and ARV-110.

5 Biopharma Stocks Making Big Moves Monday

Veru (VERU) stock is doing well on Monday after announcing positive news from a Phase 2 clinical trial of its breast cancer drug. The post VERU Stock News: 9 Things for Investors to Know About Veru Breast Cancer Trial Results appeared first on InvestorPlace.

VERU Stock News: 9 Things for Investors to Know About Veru Breast Cancer Trial Results

Do Options Traders Know Something About Veru (VERU) Stock We Don't?

-- Phase 2 Multicenter, International Clinical Study Selected as Spotlight Presentation at 2020 San Antonio Breast Cancer Symposium –

Veru Reports Positive Phase 2 Clinical Trial Results for Enobosarm, Selective Androgen Receptor Targeting Agent, for Endocrine Resistant Metastatic Breast Cancer

-- Preclinical Data Presented at the 2020 San Antonio Breast Cancer Symposium-- -- VERU-111 has Anticancer Activity in Both Paclitaxel Sensitive and Paclitaxel Resistant Triple Negative Breast Cancer Tumors-- --Veru Plans to Meet with FDA and Advance VERU-111 into a Phase 2b Clinical Trial in Women with Paclitaxel Resistant Triple Negative Breast Cancer in 2021--

VERU-111, Cytoskeleton Disruptor, Demonstrates Efficacy in Preclinical Models of Human Triple Negative Breast Cancer

Veru, Inc. (VERU) CEO Mitchell Steiner on Q4 2020 Results - Earnings Call Transcript

Shares of Veru (NASDAQ:VERU) moved higher by 4.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 160.00% year over year to $0.03, which beat the estimate of ($0.04).

Recap: Veru Q4 Earnings

-- Transformation to P remium O ncology B iopharmaceutical C ompany with L ate - S tage Clinical Drug P ipeline F ocused on P rostate and B reast C ancer is C omplete -- -- Company Poised to Initiate Four Oncology Drug Registration Trials i n Prostate and Breast Cancer in Calendar Year 2021 --

Veru Expands Oncology Drug Pipeline; Exclusively Licenses Phase 3 Clinical Stage Targeted Therapy for Endocrine Resistant Metastatic Breast Cancer

—FY20 Full-Year Net Revenue s and Gross Profit Achieve Historical Highs  o f $4 3 M illion and $ 31 M illion , Respectively—

Veru Reports Record Fiscal 2020 Fourth Quarter and Record Full-Year Financial Results

Veru (NASDAQ:VERU) releases its next round of earnings this Wednesday, December 09. Here is Benzinga's essential guide to Veru's Q4 earnings report.

Preview: Veru's Earnings

MIAMI, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that it will report financial results for its fiscal 2020 fourth quarter and full year ended September 30, 2020, on Wednesday, December 9, 2020, before the market opens.   Veru's management will host a conference call that same day at 8 a.m. ET to review the Company's performance and to answer questions. The call will also be accessible via webcast.

Veru to Report Fiscal 2020 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 9th

MIAMI, Sept.  29, 2020  (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that it has fully enrolled its Phase 2 clinical study of VERU-111, its novel, oral, alpha and beta tubulin targeting drug for metastatic castration and novel androgen receptor targeting agent resistant prostate cancer. The study enrolled a total of 40 men at 13 clinical sites in the United States.

Veru Completes Enrollment of Phase 2 Clinical Trial of VERU-111, Novel Oral Drug for Metastatic Prostate Cancer

—Advancing VERU-111 to a Pivotal Phase 3 Clinical Program—

Veru Announces ESMO Congress 2020 Oral Presentation of Positive Clinical Results from its VERU-111 Phase 1b Study in Metastatic Prostate Cancer

MIAMI, Sept.  09, 2020  (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced its participation in four upcoming healthcare investor conferences. The details for the four conferences are:

Veru to Participate and Present at Four Upcoming Healthcare Investor Conferences

Veru Inc. (VERU) CEO Mitchell Steiner on Q3 2020 Results - Earnings Call Transcript

News for Veru Stock (VERU)